ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1355	National Cancer Institute	Html	en	Rectal Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of rectal cancer.	metastatic colorectal carcinoma 0.354846 hepatic colorectal metastases 0.223514 recurrent rectal cancer 0.223407 Engl J Med 0.263348 Ann Surg 0.278325 colorectal cancer risk 0.276481 asymptomatic colorectal cancer 0.241606 colorectal cancer surgery 0.262375 metastatic colorectal cancer 0.610251 adjuvant rectal cancer 0.215149 colorectal cancer 0.902264 randomized trial 0.206269 patients 0.22566 progressive colorectal cancer 0.233252 pT3-pT4 colorectal cancer 0.254826 Clin Cancer Res 0.224834 refractory metastatic colorectal 0.227594 malignant colorectal adenomas 0.207762 et al. 0.485182 familial colorectal cancer 0.266438 colorectal liver metastases 0.255119 measurable colorectal cancer 0.232282 Dis Colon Rectum 0.282416 PUBMED Abstract 0.3294	untreated metastatic colorectal 0.230109 colorectal hepatic metastases 0.221405 advanced colorectal cancer 0.352094 irinotecan-refractory metastatic colorectal 0.231657 Colorectal lung metastases 0.222615 advanced colorectal carcinoma 0.23983 recurrent colorectal cancer 0.262817 Surg Oncol 0.226556 colorectal cancer incidence 0.264939 colorectal cancer present 0.264636 colorectal cancer disparities 0.265307 colorectal cancer group 0.277657 colorectal cancer rates 0.265187 Colorectal Study Group 0.21517 Abstract 0.47664 colon cancer 0.223051 Clin Oncol 0.752938 Colorectal cancer follow-up 0.250811 liver-limited metastatic colorectal 0.225511 Oncol Biol Phys 0.206575 dutch colorectal cancer 0.274376 Clin Colorectal Cancer 0.277838 Cancer J Clin 0.227264 colorectal carcinoma metastases 0.224249	CLICK HERE
1369	National Cancer Institute	Html	en	Oral Cavity and Oropharyngeal Cancer Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for oral cancer.	oral examination 0.527557 primary screening tool 0.417249 squamous cell tumors. 0.370971 one-time oral cancer 0.520022 systematic oral cavity 0.508919 United States 0.382344 follow-up period 0.371029 sole randomized trial 0.365707 physical examination 0.446254 cause-specific mortality benefit 0.39145 opportunistic screening 0.371936 control group 0.369767 short follow-up period 0.359545 earlier stage cancers 0.419364 randomized controlled trials 0.375895 oral visual screening 0.601987 simple hand-held device 0.363139 oral cancer mortality 0.59501 premalignant lesions 0.420448 oral visual examination 0.580404 premalignant oral lesions. 0.561468 statistically significant result 0.355967 toluidine blue staining 0.36957 direct fluorescence visualization 0.371807	blue placebo dye. 0.359062 oral cancer 0.97737 oral/pharyngeal cancers 0.364948 oral surgery 0.457512 oral cancers 0.781555 15-year follow-up period 0.369337 overall annual incidence 0.409124 overall oral cancers 0.566597 routine examination 0.355451 screening group 0.361703 subclinical high-risk fields 0.375561 oral cancer examination. 0.562099 positive predictive values 0.349612 mortality hazard ratios 0.399552 population-based screening programs 0.456558 better health outcomes. 0.355075 oral cavity 0.532106 positive test rates 0.356123 periodic health examination 0.447578 oral cancer examination 0.728118 screening setting 0.362271 screening rounds 0.355833 cause–specific mortality rate 0.408751	CLICK HERE
1422	National Cancer Institute	Html	en	Childhood Liver Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of childhood liver cancer.	unfavorable hepatoblastoma 0.444228 liver tumors 0.560678 recurrent hepatoblastoma 0.435695 pediatric hepatoblastoma 0.454465 ruptured hepatoblastoma 0.423384 metastatic hepatoblastoma 0.509586 probable hepatoblastoma 0.453029 Eur J Cancer 0.388707 international pediatric liver 0.386143 multiply relapsed hepatoblastoma 0.447121 children 0.485632 Hepatoblastoma clinical research 0.47139 standard-risk hepatoblastoma 0.42407 clinical trials 0.40571 apparently sporadic hepatoblastoma 0.4599 weight hepatoblastoma cases 0.474502 Hepatoblastoma state 0.437405 International Society 0.406829 PRETEXT group assignment 0.412995 pediatric liver 0.555337 small cell hepatoblastoma 0.447198 pediatric liver tumors 0.460989 childhood hepatoblastoma 0.480002 pediatric liver resection 0.388074 familial adenomatous polyposis 0.407751	et al. 0.704223 congenital hepatoblastoma 0.4367 unresectable hepatoblastoma cases 0.452922 surgical resection 0.477903 PUBMED Abstract 0.546371 Pediatr Blood Cancer 0.795718 paediatric hepatoblastoma 0.439301 pediatric liver tumor 0.53573 advanced hepatoblastoma 0.46193 childhood liver cancer 0.393775 Liver Tumor Study 0.447606 newly diagnosed hepatoblastoma 0.454459 Pediatr Surg 0.416351 Abstract 0.708564 Pediatr Hematol Oncol 0.541505 Clin Oncol 0.519738 unresectable hepatoblastoma 0.472209 complete surgical resection 0.406131 hepatoblastoma 0.939626 high-risk hepatoblastoma 0.561704 childhood high-risk hepatoblastoma 0.538739 Oncology Liver Tumor 0.378181 hepatoblastoma patients 0.439703 Oncology Group 0.393362	CLICK HERE
1650	National Cancer Institute	Html	en	Selected Vegetables/Sun's Soup (PDQ®)–Patient Version	Expert-reviewed information summary about the use of selected vegetables/Sun's soup as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	treatment 0.620935 cancer treatment 0.517212 cancer prevention 0.486935 Complementary Therapies Editorial 0.534234 United States 0.494682 Well-designed clinical trials 0.477309 Drug Administration 0.522277 Cancer Information Specialist 0.498157 cancer cells 0.558873 Cancer Information Service 0.567973 PDQ cancer information 0.645069 Cancer Complementary 0.510973 PDQ Selected Vegetables/Sun 0.52487 Vegetables/Sun’s Soup 0.718967 CAM therapies 0.498393 Soup ingredients 0.49536 treatment clinical trials 0.493338 National Cancer Institute 0.676034 clinical trials 0.788657 alternative medicine 0.562862 standard food 0.487423 conventional treatment 0.48119 cancer information summary 0.571239 alternative cancer therapies 0.505071	Federal Trade Commission 0.49349 National Institutes 0.486354 clinical trial 0.532528 new treatment 0.541852 mung bean 0.494966 CAM cancer research 0.493212 breast cancer prevention 0.484457 shiitake mushroom 0.517658 patients 0.594168 cancer patients 0.547142 new treatment works 0.477537 Cancer Care page 0.486585 health 0.482953 Selected Vegetables/Sun 0.982781 PDQ summary 0.47773 non-small cell lung 0.519358 NCI PDQ cancer 0.530378 cancer information database 0.505237 cell lung cancer 0.547396 alternative therapies 0.532329 cancer information summaries 0.505491 Frozen Selected Vegetables 0.492972 Therapies Editorial Board 0.515019	CLICK HERE
1737	National Cancer Institute	Html	en	Lasers in Cancer Treatment	A fact sheet that describes use of high-intensity light in cancer treatment, its advantages and disadvantages, and types of procedures that use it.	cancer treatment 0.596049 flexible endoscope 0.380536 health care provider 0.409067 body 0.411001 argon lasers 0.532774 high-intensity light 0.445412 clinical trials 0.451803 bright indoor light 0.427495 LITT 0.389656 Laser-induced interstitial thermotherapy 0.422778 seal lymph vessels 0.416005 specific wavelength 0.3683 lower risk 0.371973 laser light 0.694799 normal tissue 0.366241 clinical trials page 0.408776 Ordinary light 0.384552 radiation therapy 0.382841 powerful beam 0.363945 NCI fact sheet 0.529266 light bulb 0.385224 sheet Photodynamic Therapy 0.436155 standard surgical tools 0.542942 photodynamic therapy 0.436739 early stages 0.365543	optical fibers 0.421684 fact sheet Hyperthermia 0.42197 cancer cells 0.463993 colon polyps 0.373762 cell skin cancer 0.441978 Cancer Information Service 0.427676 interstitial laser photocoagulation 0.453094 lasers 0.686527 strict safety precautions 0.41161 precancerous growths 0.534102 light amplification 0.39079 laser surgery 0.440343 patient 0.366006 tumor cells 0.428295 PDT 0.367707 nerve endings 0.364934 precise surgical work 0.423122 superficial cancers 0.447776 YAG laser light 0.46252 laser therapy 0.900564 tumors 0.382431 cell lung cancer 0.440229 tiny areas 0.365703 narrow beam 0.364464	CLICK HERE
1992	National Cancer Institute	Html	es	Tratamiento del tumor teratoideo/rabdoide atípico del sistema nervioso central infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de los tumores teratoideos/rabdoides atípicos del sistema nervioso central infantil.	tumores smarcb1 0.603767 células madre 0.629225 efectos secundarios meses 0.607017 siguientes aspectos 0.601615 siguientes especialistas 0.601426 genes smarcb1 0.609598 PDQ Descripción 0.60415 efectos tardíos 0.611777 PDQ Tumores 0.606157 PDQ Efectos tardíos 0.604371 National Cancer Institute 0.601403 siguientes riesgos 0.600917 profesional entrenado 0.601618 Instituto Nacional 0.6024 PDQ Tratamiento 0.603883	presente sumario 0.602507 determinados cambios 0.601063 presente sección 0.601013 nuevos tipos 0.601364 sistema nervioso central 0.98418 Physician Data Query 0.604988 brain tumor 0.602951 Aboutâ„¢ Brain Tumors 0.601752 ensayos clínicos.Terapia 0.60282 siguientes terapias 0.601133 siguientes enlaces 0.601027 Brain Tumor Consortium 0.605055 panel derecho 0.601581 siguientes trastornos 0.601436	CLICK HERE
2051	National Cancer Institute	Html	es	Vacunas contra el cáncer	Hoja informativa que define los tipos de vacunas y explica cómo funcionan, cómo se preparan, y describe la investigación relacionada con su uso.	stemness-related tumor 0.305626 Mortality Weekly Report 0.305127 cancer vaccines 0.384507 células t 0.36244 células apc 0.361199 immune system 0.308685 proteína llamada factor 0.306202 vacunas protegen 0.338385 promising treatment modality 0.305201 beyond current paradigms 0.30561 hepatitis b 0.31173 Estados Unidos 0.331683 Expert Opinion 0.310074 fuerte respuesta 0.312982 Sipuleucel-T immunotherapy 0.305397 PubMed Abstract 0.971511 fuertes respuestas 0.305062 tumor antigen discovery 0.307826 proteína llamada 0.309122 vacunas autólogas 0.332195 invasores foráneos 0.325813 papiloma humano tipos 0.309997 Therapeutic vaccines as 0.30821 British Medical Journal 0.305786 therapy through immunomodulation 0.306217	frecuencia citocinas 0.305145 Schlom J 0.308012 suficientes antígenos 0.322846 factor estimulador 0.309823 programmed cell death 0.30504 inmunitario llamadas células 0.349485 moving beyond current 0.316247 comprehensive immunization strategy 0.30562 vacunas alogénicas 0.333841 cabo respuestas 0.305615 Reviews Cancer 0.310845 Mutant MHC class 0.305006 TRICOM vector based 0.304939 stable metastatic breast 0.304849 Current Pharmaceutical Design 0.305726 Therapeutic Advances 0.304747 cuello uterino 0.354099 mutational neoepitopes reveals 0.305636 tumor model 0.304956 Clinical Cancer Research 0.341107 Gulley JL 0.308772 vacunas resultantes 0.336516 New England Journal 0.315061 células renales 0.33154	CLICK HERE
3564	National Cancer Institute	Html	en	The NCI Intramural Research Program	The intramural research program supports projects conducted by scientists located at NCI.	intramural cancer research 0.718907 intramural research program 0.874728 public health issues 0.586317 IRP researchers 0.99482 clinical disciplines 0.535611 basic research discovery 0.633697 cancer initiation 0.556039 NCI offices 0.598153 private sector partners 0.575197 long-term cohort studies 0.573663 NCI intramural research 0.823709 extramural institutions 0.555913 future research 0.545095 clinical trials 0.610273 sophisticated statistical approaches 0.591904 outstanding scientific credentials 0.582191 rare cancers 0.616347 outstanding research 0.546529 clinical IRP researchers 0.677303 extramural investigators 0.808101 basic scientific research 0.670523 cervical cancer 0.590079 traditional funding mechanisms 0.574359 Early-stage clinical trials 0.595705	intramural researchers 0.664665 Cancer Epidemiology 0.564756 population-based research 0.591379 various reasons—to fund 0.579705 National Cancer Program 0.628399 cancer prevention 0.546859 noninfectious virus-like particles 0.5887 relatively little funding 0.573973 cancer research 0.783668 academic institutions 0.606037 high-reward research 0.541951 NCI IRP 0.623146 CCR’s John 0.543838 NIH Clinical Center 0.948229 public health needs 0.603453 Intramural research projects 0.689496 research program complement 0.627977 basic cancer research 0.675487 research resources 0.556851 CCR researcher Ira 0.613887 NCI components 0.59726 CCR colleagues 0.538611 cancer risk 0.53862 federal government investigators 0.655439	CLICK HERE
3605	National Cancer Institute	Html	en	Enhancing Drug Discovery and Development	The discovery and development of new therapeutic agents for cancer is essential for continued progress against the disease. Historically, NCI has played a vital role in cancer drug discovery and development, and, today, that role continues. Frequently, NCI’s drug development efforts focus on unmet needs that are not being adequately addressed by the private sector.	human tumor cell 0.493589 Developmental Therapeutics Program 0.373741 cell lines 0.756764 corresponding cancer types 0.401362 primary cancer cells 0.471158 drug discovery 0.918943 cell line panel 0.382826 long-term cell cultures 0.381121 drug screening 0.363881 development activities 0.393342 human cancer models 0.633791 human tumor samples 0.437784 precision medicine 0.432081 congressionally mandated initiative 0.360908 human cancer cell 0.54738 drug resistance 0.374751 tyrosine kinase inhibitor 0.365397 drug development efforts 0.451048 potential anticancer agents 0.404376 traditional cell lines 0.391913 parental tumors 0.388039 routine cancer care 0.38291 Cancer Treatment 0.353066 cancer cells 0.647891 cancer cell lines 0.473566	new human cancer 0.517038 cancer cell biology 0.425139 NCI Experimental Therapeutics 0.397544 tumor sections 0.354283 cell line screen 0.52167 largest cancer pharmacology 0.402164 cell culture techniques 0.37598 NCI-60 cell line 0.515114 drug discovery program 0.435482 NIH Clinical Center 0.354806 cancer stem cells 0.444759 anticancer drug discovery 0.568944 biologic agent discovery 0.381604 new therapeutic agents 0.383079 Cancer Chemotherapy National 0.425183 NCI’s anticancer 0.350161 clinical development resources 0.397358 NCI’s drug 0.370038 original tumor 0.350461 normal cell counterparts 0.370786 cancer drug discovery 0.678381 Human cancer cells 0.468312 multiple cell types 0.380725 tumor microenvironment 0.401449	CLICK HERE
16846	National Cancer Institute	Html	en	The University of Texas MD Anderson Cancer Center—Targeted Therapeutics for Ovarian Cancer and its Microenvironment – Treatment and Theoretical Modeling	Will offer nanotherapeutic formulations and novel approaches targeting multiple components of the tumor and its microenvironment, specifically for high-grade serous ovarian cancers.	Anil Sood 0.374281 critical molecular targets 0.456713 significant role 0.350306 ovarian cancer models 0.573698 Gabriel Lopez-Berestein 0.357257 monocyte-macrophage axis 0.343069 dual effect nanoparticles 0.489182 tumor-associated macrophages 0.355321 tumor microenvironment interactions 0.655973 significant antitumor activity 0.470227 five-year mortality rates 0.488005 AXL aptamers 0.532934 AXL-receptor binding aptamers 0.494135 specific AXL aptamers 0.512408 eventual tumor growth 0.616726 ovarian cancer 0.98899 gene silencing molecules 0.467313 current regimens 0.384525 Lokesh sRao 0.372622 Principal Investigators 0.351287 therapeutic nanoparticles 0.389578 maximal anti-tumor efficacy 0.546141 tumor progression 0.503786 Vittorio Cristini 0.380084 therapeutic efficacy 0.513726	Zhihui Wang 0.359239 nanoparticle surface 0.346896 nanoparticle effects 0.34271 drug resistance 0.343585 Sunila Pradeep 0.383374 tumor-promoting TAMs 0.351562 slow-release dual assembly 0.461875 MMA cell accumulation 0.438136 particularly attractive approach 0.453092 deadliest gynecological cancer 0.510101 tumor growth 0.640954 tumor cells 0.528853 David Volk 0.359179 platinum/taxane-based regimens 0.397302 optimal dosing regimens 0.492748 efficacy profiles 0.393175 high mortality rates 0.477298 multipronged dosing schedules 0.45156 Bulent Ozpolat 0.372014 slow release DANPs 0.440473 Traditional therapy 0.34917 serous ovarian cancer 0.612409 cancer biology 0.356075 tumor microenvironment 0.813294	CLICK HERE